CLINICAL TRIALS

The University of Virginia Department of Dermatology is home to the Institute for Dermatologic Research and Advancement (IDRA), which is focused on investigator-initiated as well as commercial/industry-sponsored research endeavors.

Our goal is to first and foremost provide the most up to date dermatologic care for our patients while advancing knowledge of cutaneous disease. IDRA is actively recruiting clinical trials in psoriasis, vascular anomalies, neurocutaneous disease, procedural dermatology, cutaneous malignancy, alopecia areata, graft-versus-host disease and others.

For more information about IDRA or participation in clinical trials, please contact IDRA Research Coordinator: Lauren Kuhns at LRK9T@virginia.edu

We are recruiting patients with Fitzpatrick skin types III-VI who have facial and non-facial vitiligo. This trial investigates the effectiveness of Afamelanotide, a synthetic agonist of the MC1R receptor, in combination with narrowband UVB therapy.

This trial is for HS patients who have not responded to adalimumab treatment. JAK inhibitors are showing early promise for HS, and Upadacitinib (already approved for atopic dermatitis and inflammatory arthritis) is being studied in this trial.

This study for patients with cutaneous vasculitis compares dapsone, colchicine, and azathioprine. Idiopathic, IgA and other types of skin predominant vasculitis are included.

We are preparing for early fall activation for the use of Anifrolumab, an interferon receptor inhibitor already approved for systemic lupus erythematosus (SLE), in treating discoid and subacute cutaneous lupus. Patients in this trial will have cutaneous lupus but not systemic lupus.

This study is for evaluating the use of an innovative care coordination model in lowering cardiovascular risk in patients with psoriatic disease.

Care coordinators meet with enrolled patients living with psoriasis who have an elevated risk of CVD and guide them through their CVD risk calculations, review their risk profile, help develop a diet, exercise, and medication plan, and connect them with a primary care provider.

Inclusion criteria:
– Have psoriasis treated by a dermatologist
– Are age 40-75 years old
– Have no known history of cardiovascular disease
– Are not currently on a prescription medication to treat cholesterol